Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT05198934	TitleSotorasib and Panitumumab Versus Investigator’s Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak 300)	Phase Phase 3	Date Added 2022-01-20	Location Alabama, United States California, United States District of Columbia, United States Florida, United States Georgia, United States Michigan, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia France Germany Greece Italy Japan Korea, Republic of Mexico Spain Taiwan United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05194735	TitlePhase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors	Phase Phase 1	Date Added 2022-01-18	Location Texas, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Aldesleukin (IL-2), Neoantigen specific TCR-T cell drug product	Tags MSS/ MMRp
NCT ID NCT05167409	TitleA Study of ALX148 With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer	Phase Phase 2	Date Added 2021-12-22	Location Arizona, United States Colorado, United States New Jersey, United States Virginia, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs ALX148, cetuximab, Evorpacept (ALX148), Pembrolizumab, Erbitux, Keytruda	Tags MSS/ MMRp
NCT ID NCT05141721	TitleA Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer	Phase Phase 2	Date Added 2021-12-02	Location Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Maryland, United States Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Wisconsin, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Atezolizumab, Bevacizumab, Fluoropyrimidine, GRT-C901, GRT-R902, Ipilimumab, oxaliplatin	Tags MSS/ MMRp
NCT ID NCT05141474	TitleAssessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors	Phase Early Phase 1	Date Added 2021-12-02	Location Spain	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs Interleukin-2, NEXTGEN-TIL, Non-myeloablative Lymphodepletion (NMA-LD) Regimen	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05107674	TitleA Study of NX-1607 in Adults With Advanced Malignancies	Phase Phase 1	Date Added 2021-11-04	Location California, United States Colorado, United States Illinois, United States North Carolina, United States Oklahoma, United States Texas, United States Virginia, United States Washington, United States United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs NX-1607	Tags MSS/ MMRp
NCT ID NCT05019534	TitleTolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer	Phase Phase 1	Date Added 2021-08-25	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Camrelizumab, Cetuximab Injection [Erbitux], Vemurafenib Oral Tablet [Zelboraf]	Tags MSS/ MMRp
NCT ID NCT04991948	TitleStudy of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer	Phase Phase 1	Date Added 2021-08-05	Location Florida, United States Belgium	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs CYAD-101, FOLFOX, Pembrolizumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04984369	TitleThe Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment	Phase Phase 2	Date Added 2021-07-30	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Cetuximab Injection [Erbitux], HLX208	Tags MSS/ MMRp
NCT ID NCT04973163	TitleA Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation	Phase Phase 1	Date Added 2021-07-22	Location Texas, United States Belgium Spain United Kingdom	Prior IO Allowed No	CRC-directed No	Status Active, not recruiting	Drugs BI 1701963, BI 1823911, Midazolam	Tags MSS/ MMRp

Showing 121 to 130 of 299 entries